ラジオセラノスティクスの世界市場、放射性同位体別 (テクネチウム-99、ガリウム-68、ヨウ素-131、ヨウ素-123、18F、Y-90、ルテチウム177、銅67、銅64、その他)・用途別・エンドユーザー別・地域別：競合・予測・機会 (2027年)

世界のラジオセラノスティクス市場は、予測期間 (2023年～2027年) に目覚ましいCAGRで成長を記録すると予測されています。

ラジオセラノスティクスは、画像診断と治療薬のペアで放射性核種を使用するプロセスです。これは、標的診断薬と治療薬の体系的な統合です。がんの有病率の増加と、抗腫瘍効果を持つ注射用放射性医薬品の採用が増加していることが、世界のラジオセラノスティクス市場の成長に大きく寄与しています。さらに、放射線治療薬のイノベーションの現在の勢いに歩調を合わせるための研究開発への継続的な支援は、市場の成長を支えています。さらに、がんの基礎となる生物学の理解や、標的治療薬の合成・設計方法の強化に成功したことで、放射線治療薬の臨床使用は劇的に増加しました。このことは、市場の成長にプラスの影響を与えています。

当レポートでは、世界のラジオセラノスティクスの市場について分析し、全体的な市場規模の動向見通しや市場シェア構造 (放射性同位体別・用途別・エンドユーザー別)、地域別・主要国の詳細動向、主な市場促進・抑制要因、企業間の市場競争構造、主要企業のプロファイル、今後の市場成長の方向性などを調査しております。

目次

第1章 製品概要

第2章 分析方法

第3章 エグゼクティブサマリー

第4章 世界のラジオセラノスティクス市場に対するCOVID-19の影響

第5章 顧客側の見解

• 放射線治療の認識
• がんの有病率：男女別
• がんの有病率：年齢層別
• がんの有病率：地域別
• 放射線治療を使用する利点

第6章 臨床試験分析

第7章 特許分析

第8章 世界のラジオセラノスティクス市場：将来展望

• 市場規模とその予測
  • 金額ベース
• 市場シェアとその予測
  • 放射性同位体別 (テクネチウム-99、ガリウム-68、ヨウ素-131、ヨウ素-123、18F、Y-90、ルテチウム (Lu) 177、銅 (Cu) 67、銅 (Cu) 64、その他)
  • 用途別 (腫瘍 vs 非腫瘍)
  • エンドユーザー別 (病院・クリニック、製薬・バイオテクノロジー企業、その他)
  • 地域別
  • 企業別 (2021年)
• 製品市場マップ

第9章 北米のラジオセラノスティクス市場の見通し

• 市場規模とその予測
• 市場シェアとその予測
• 北米：国別分析
  • 米国のラジオセラノスティクス市場の見通し
  • メキシコのラジオセラノスティクス市場の見通し
  • カナダのラジオセラノスティクス市場の見通し

第10章 欧州のラジオセラノスティクス市場の見通し

• 市場規模とその予測
• 市場シェアとその予測
• 欧州：国別分析
  • フランスのラジオセラノスティクス市場の見通し
  • ドイツのラジオセラノスティクス市場の見通し
  • 英国のラジオセラノスティクス市場の見通し
  • イタリアのラジオセラノスティクス市場の見通し
  • スペインのラジオセラノスティクス市場の見通し

第11章 アジア太平洋のラジオセラノスティクス市場の見通し

• 市場規模とその予測
• 市場シェアとその予測
• アジア太平洋：国別分析
  • 中国のラジオセラノスティクス市場の見通し
  • インドのラジオセラノスティクス市場の見通し
  • 韓国のラジオセラノスティクス市場の見通し
  • 日本のラジオセラノスティクス市場の見通し
  • オーストラリアのラジオセラノスティクス市場の見通し

第12章 南米のラジオセラノスティクス市場の見通し

• 市場規模とその予測
• 市場シェアとその予測
• 南米：国別分析
  • ブラジルのラジオセラノスティクス市場の見通し
  • アルゼンチンのラジオセラノスティクス市場の見通し
  • コロンビアのラジオセラノスティクス市場の見通し

第13章 中東・アフリカのラジオセラノスティクス市場の見通し

• 市場規模とその予測
• 市場シェアとその予測
• 中東・アフリカ：国別分析
  • 南アフリカのラジオセラノスティクス市場の見通し
  • サウジアラビアのラジオセラノスティクス市場の見通し
  • アラブ首長国連邦のラジオセラノスティクス市場の見通し

第14章 市場力学

• 促進要因
• 課題

第15章 市場の動向と発展

第16章 SWOT分析：世界のラジオセラノスティクス市場

第17章 競合情勢

• TransCode Therapeutics, Inc.
• Curium SAS
• GE Healthcare Inc.
• Bayer AG
• Lantheus Medical Imaging, Inc.
• Novartis AG
• Spectrum Pharmaceuticals, Inc.
• Ipsen S.A.
• Actinium Pharmaceuticals, Inc. (ATNM)
• Nordic Nanovector ASA
• Y-mAbs Therapeutics, Inc.
• Sofie Biosciences, Inc.
• Terumo Corporation
• Sirtex Medical Limited
• Boston Scientific Corporation

第18章 戦略的提言

Global radiotheranostics market is anticipated to register growth at an impressive CAGR in the forecast period, 2023-2027. Radiotheranostics is a process that involves the use of radionuclides for paired imaging and therapy agents. It is a systematic integration of targeted diagnostics and therapeutics. The growing prevalence of cancer and the rising adoption of injectable radiopharmaceuticals that have antitumor effects are majorly contributing to the global radiotheranostics market growth. The increasing usage of radiotheranostics in cancer diagnosis and management is providing a thrust to the market. Radiotheranostics have enhanced therapy efficacy, the ability to manage adverse and critical health situations, which results in improved patient outcomes.

Moreover, the recent research and developments in the radiotheranostics field is creating a positive impact on the market growth. For instance, there have been major outcomes in radiotheranostics for prostate cancer and neuroendocrine tumors. Additionally, the regulatory approval of numerous radiotheranostics pairs is expected to boost their adoption for cancer treatments. For instance, the approvals of new radiotheranostics agents such as 177Lu-PSMA-617 and 177Lu-DOTATATE have resulted in the resurgence of research in the field of radiotheranostics and have proliferated the number of clinical trials and testing several other novel radiotheranostics. Furthermore, the continuous support in research and development to keep pace with current momentum in radiotheranostics innovations is supporting the market growth. Additionally, the clinical use of radiotheranostics agents have increased dramatically due to the successful strides that have been made in the understanding of underlying biology of cancer and enhanced methods for synthesizing and designing targeted theragnostic agents. This, in turn, is positively influencing the market growth.

Structural imaging is the most crucial component of staging, diagnosing, and assessing responses in cancer patients. However, patients and healthcare professionals are increasingly seeking non-invasive methods of investigating tumor phenotypes and assessing molecular and functional responses to therapy. Therefore, radiotheranostics, a combination of non-invasive diagnostic imaging with targeted therapy, is widely being implemented. As a result, the global market for radiotheranostics is anticipated to propel at a rapid pace in the coming years.

Market Segmentation

The global radiotheranostics market is segmented by radioisotope, application, end user, competitive landscape, and regional distribution. Based on the radioisotope, the market is differentiated between technetium-99, gallium-68, iodine-131, iodine-123, 18f, y-90, lutetium (lu) 177, copper (cu) 67, copper (cu) 64, and others. By offering the market is fragmented between oncology and non-oncology. The oncology segment is further bifurcated into thyroid cancer, neuroendocrine cancer, hepatocellular carcinoma, multiple myeloma and lymphoma, and other. The non-oncology application segment is further divided between joint infections, arthritis, bone pain, and others. On the basis of end user, the global market is segmented between hospitals & clinics, pharmaceutical & biotechnology companies, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among North America, Europe, Asia Pacific, Middle east and Africa, South America.

Company Profile

TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, and Boston Scientific Corporation are the leading market players responsible for the growth of global radiotheranostics market.

Report Scope:

In this report, global radiotheranostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Radiotheranostics Market, By Radioisotope:

• Technetium-99
• Gallium-68
• Iodine-131
• Iodine-123
• 18F
• Y-90
• Lutetium (Lu) 177
• Copper (Cu) 67
• Copper (Cu) 64
• Others

Global Radiotheranostics Market, By Application:

• Oncology
  • Thyroid Cancer
  • Neuroendocrine Cancer
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Lymphoma, Others

• Non-Oncology
  • Joint Infections
  • Arthritis
  • Bone Pain
  • Others
  • Global Radiotheranostics Market, By End User:

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Others

Global Radiotheranostics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

• South America
  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global radiotheranostics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Radiotheranostics Market

5. Voice of Customer

• 5.1. Radiotheranostics Awareness
• 5.2. Cancer Prevalence, By Gender
• 5.3. Cancer Prevalence, By Age Group
• 5.4. Cancer Prevalence, Region
• 5.5. Benefits of Using Radiotheranostics

6. Clinical Trial Analysis

7. Patent Analysis

8. Global Radiotheranostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 8.2.2. By Application (Oncology v/s Non-Oncology)
    • 8.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 8.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 8.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 8.2.4. By Region
  • 8.2.5. By Company (2021)
• 8.3. Product Market Map

9. North America Radiotheranostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 9.2.2. By Application (Oncology v/s Non-Oncology)
    • 9.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 9.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 9.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 9.2.4. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Radiotheranostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Radioisotope
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Mexico Radiotheranostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Radioisotope
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Canada Radiotheranostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Radioisotope
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Europe Radiotheranostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 10.2.2. By Application (Oncology v/s Non-Oncology)
    • 10.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 10.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 10.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 10.2.4. By Country
• 10.3. Europe: Country Analysis
  • 10.3.1. France Radiotheranostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Radioisotope
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Germany Radiotheranostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Radioisotope
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. United Kingdom Radiotheranostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Radioisotope
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User
  • 10.3.4. Italy Radiotheranostics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Radioisotope
      • 10.3.4.2.2. By Application
      • 10.3.4.2.3. By End User
  • 10.3.5. Spain Radiotheranostics Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Radioisotope
      • 10.3.5.2.2. By Application
      • 10.3.5.2.3. By End User

11. Asia-Pacific Radiotheranostics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 11.2.2. By Application (Oncology v/s Non-Oncology)
    • 11.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 11.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 11.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 11.2.4. By Country
• 11.3. Asia-Pacific: Country Analysis
  • 11.3.1. China Radiotheranostics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Radioisotope
      • 11.3.1.2.2. By Application
      • 11.3.1.2.3. By End User
  • 11.3.2. India Radiotheranostics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Radioisotope
      • 11.3.2.2.2. By Application
      • 11.3.2.2.3. By End User
  • 11.3.3. South Korea Radiotheranostics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Radioisotope
      • 11.3.3.2.2. By Application
      • 11.3.3.2.3. By End User
  • 11.3.4. Japan Radiotheranostics Market Outlook
    • 11.3.4.1. Market Size & Forecast
      • 11.3.4.1.1. By Value
    • 11.3.4.2. Market Share & Forecast
      • 11.3.4.2.1. By Radioisotope
      • 11.3.4.2.2. By Application
      • 11.3.4.2.3. By End User
  • 11.3.5. Australia Radiotheranostics Market Outlook
    • 11.3.5.1. Market Size & Forecast
      • 11.3.5.1.1. By Value
    • 11.3.5.2. Market Share & Forecast
      • 11.3.5.2.1. By Radioisotope
      • 11.3.5.2.2. By Application
      • 11.3.5.2.3. By End User

12. South America Radiotheranostics Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 12.2.2. By Application (Oncology v/s Non-Oncology)
    • 12.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 12.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 12.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 12.2.4. By Country
• 12.3. South America: Country Analysis
  • 12.3.1. Brazil Radiotheranostics Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Radioisotope
      • 12.3.1.2.2. By Application
      • 12.3.1.2.3. By End User
  • 12.3.2. Argentina Radiotheranostics Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Radioisotope
      • 12.3.2.2.2. By Application
      • 12.3.2.2.3. By End User
  • 12.3.3. Colombia Radiotheranostics Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Radioisotope
      • 12.3.3.2.2. By Application
      • 12.3.3.2.3. By End User

13. Middle East and Africa Radiotheranostics Market Outlook

• 13.1. Market Size & Forecast
  • 13.1.1. By Value
• 13.2. Market Share & Forecast
  • 13.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 13.2.2. By Application (Oncology v/s Non-Oncology)
    • 13.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
    • 13.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
  • 13.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 13.2.4. By Country
• 13.3. MEA: Country Analysis
  • 13.3.1. South Africa Radiotheranostics Market Outlook
    • 13.3.1.1. Market Size & Forecast
      • 13.3.1.1.1. By Value
    • 13.3.1.2. Market Share & Forecast
      • 13.3.1.2.1. By Radioisotope
      • 13.3.1.2.2. By Application
      • 13.3.1.2.3. By End User
  • 13.3.2. Saudi Arabia Radiotheranostics Market Outlook
    • 13.3.2.1. Market Size & Forecast
      • 13.3.2.1.1. By Value
    • 13.3.2.2. Market Share & Forecast
      • 13.3.2.2.1. By Radioisotope
      • 13.3.2.2.2. By Application
      • 13.3.2.2.3. By End User
  • 13.3.3. UAE Radiotheranostics Market Outlook
    • 13.3.3.1. Market Size & Forecast
      • 13.3.3.1.1. By Value
    • 13.3.3.2. Market Share & Forecast
      • 13.3.3.2.1. By Radioisotope
      • 13.3.3.2.2. By Application
      • 13.3.3.2.3. By End User

14. Market Dynamics

• 14.1. Drivers
• 14.2. Challenges

15. Market Trends & Developments

16. SWOT Analysis: Global Radiotheranostics Market

17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)

• 17.1. TransCode Therapeutics, Inc.
• 17.2. Curium SAS
• 17.3. GE Healthcare Inc.
• 17.4. Bayer AG
• 17.5. Lantheus Medical Imaging, Inc.
• 17.6. Novartis AG
• 17.7. Spectrum Pharmaceuticals, Inc.
• 17.8. Ipsen S.A.
• 17.9. Actinium Pharmaceuticals, Inc. (ATNM)
• 17.10. Nordic Nanovector ASA
• 17.11. Y-mAbs Therapeutics, Inc.
• 17.12. Sofie Biosciences, Inc.
• 17.13. Terumo Corporation
• 17.14. Sirtex Medical Limited
• 17.15. Boston Scientific Corporation

18. Strategic Recommendations

(Note: The companies list can be customized based on the client requirements.)